Genetic engineering of stent grafts with a highly efficient pseudotyped retroviral vector

Eton, Darwin; Terramani, Thomas T.; Wang, Ying; Takahashi, Aileen M.; Nigro, John J.; Tang, Lili; Yu, Hong

doi:10.1016/s0741-5214(99)70214-4

Cited by 24 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isolation of EC and SMC Human saphenous vein endothelial cells (HSVEC) and SMC were isolated as described previously 28 from excreta human saphenous veins obtained from patients undergoing bypass surgery at the University of Southern California Hospitals. The protocol for using excreta human vein was approved by the Institutional Review Board (IRB No.…”

Section: Methodsmentioning

confidence: 99%

“…28 Briefly, 293T/17 cells were transfected by calcium phosphate precipitation with plasmids pCnBgSN, pHIT60, and pCVG for VSV-G/MuLV or pCAE for Ampho/MuLV (Figure 1). The viral supernatants were harvested after sodium butyrate treatment, and the viral infectious titers were analyzed with both G418-resistant colony formation and ␤-galactosidase activity assay.…”

Section: Retroviral Production and Titer Determinationmentioning

confidence: 99%

“…28 Briefly, rectangular (5 × 10 mm) vein patches were pinned down with two 25-gauge needles, luminal surface facing upwards, in a 60 × 20 mm Petri dish having a 6 mm layer of Sylgard 184 resin cured (Dow Corning, Midland, MI, USA) in its base. Vein segments were cultured with Williams' medium supplemented with 2 g/l sodium bicarbonate (Gibco/BRL), antibiotics as mentioned in Cell culture, 2 mm l-glutamine, and 30% (v/v) FBS.…”

Section: Transduction Of Svmentioning

confidence: 99%

See 2 more Smart Citations

High efficiency in vitro gene transfer into vascular tissues using a pseudotyped retroviral vector without pseudotransduction

Eton

Wang

et al. 1999

Gene Ther

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Retroviral Production and Titer Determinationmentioning

confidence: 99%

Section: Transduction Of Svmentioning

confidence: 99%

See 1 more Smart Citation

High efficiency in vitro gene transfer into vascular tissues using a pseudotyped retroviral vector without pseudotransduction

Eton

Wang

et al. 1999

Gene Ther

View full text Add to dashboard Cite

“…These vectors infect cultured endothelial cells from different sources with moderate efficiency (online Table I). [81][82][83][84] Recently, we showed that pseudotype retroviral vectors derived from murine stem cell virus originally developed by Hawley et al 85 transduce EPC with very high efficiency. 9,86 Furthermore, we observed transgene expression in vivo up to 1 month after transplantation of the cells in injured blood vessels, suggesting that this vector may be suitable for genetic modification and long-term expression of therapeutic genes by EPC in vivo.…”

Section: Tools For Genetic Manipulation Of the Endothelium Vectorsmentioning

confidence: 99%

“…79 Nevertheless, retroviral vectors have been used extensively for ex vivo genetic modification of proliferating endothelial cells and EPC for subsequent implantation in vivo. 9,[81][82][83][84] Most of the retroviral vectors in current use are derived form Moloney murine leukemia virus. These vectors infect cultured endothelial cells from different sources with moderate efficiency (online Table I).…”

mentioning

confidence: 99%

Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease

Melo

Gnecchi

Pachori

et al. 2004

ATVB

View full text Add to dashboard Cite

Abstract-Most common cardiovascular diseases are accompanied by endothelial dysfunction. Because of its predominant role in the pathogenesis of cardiovascular disease, the vascular endothelium is an attractive therapeutic target. The identification of promoter sequences capable of rendering endothelial-specific transgene expression together with the recent development of vectors with enhanced tropism for endothelium may offer opportunities for the design of new strategies for modulation of endothelial function. Such strategies may be useful in the treatment of chronic diseases such as hypertension, atherosclerosis, and ischemic artery disease, as well as in acute myocardial infarction and during open heart surgery for prevention of ischemia and reperfusion (I/R)-induced injury. The recent identification of putative endothelial progenitor cells in peripheral blood may allow the design of autologous cell-based strategies for neovascularization of ischemic tissues and for the repair of injured blood vessels and bioengineering of vascular prosthesis. "Proof-of-concept" for some of these strategies has been established in animal models of cardiovascular disease. However the successful translation of these novel strategies into clinical application will require further developments in vector and delivery technologies. Further characterization of the processes involved in mobilization, migration, homing, and incorporation of endothelial progenitor cells into the target tissues is necessary, and the optimal conditions for therapeutic application of these cells need to be defined and standardized. T he vascular endothelium (VE) plays a pivotal role in the regulation of vascular function and homeostasis. 1 In normal conditions, the VE elaborates a variety of substances that influence vascular tone and protect the vessel wall against inflammatory cell adhesion, thrombus formation, and vascular cell proliferation. [2][3][4] Pathological conditions caused by increased oxidative stress, hyperlipidemia, and inflammation lead to endothelial dysfunction, which is characterized by reduced availability of vasodilatory and anti-adhesion substances, such as nitric oxide (NO) and prostacyclin, and concomitant increases in vasoconstrictor and pro-adhesion factors such as endothelin-1, angiotensin II, and thromboxanes 4 (Figure 1). These changes lead to increased vascular tone, inflammatory cell and platelet adhesion, and proliferation of the media smooth muscle, which increase the occurrence of thrombosis and vascular occlusion. 3,4 Because of its central role in the pathogenesis of cardiovascular disease, the endothelium is an attractive therapeutic target for cardiovascular disease. 5 Genetic modulation of endothelial function may offer new opportunities to modify the course of common cardiovascular diseases such as hypertension, atherosclerosis, thrombosis, and ischemic artery disease, whereas the availability of endothelial progenitor cells (EPC) 6 may allow the design of cell-based strategies for rescue of ischemic tissue and rep...

show abstract

Enhanced retroviral transduction of 293 cells cultured on liquid-liquid interfaces

Kwon

Peng

2000

Biotechnol. Bioeng.

Self Cite

View full text Add to dashboard Cite

In clinical research, retrovirus‐mediated gene therapy is one of the most commonly used methods to deliver and express the gene of interest due its ability to allow for stable gene integration into the chromosomes of target cells. To elevate the efficiency of viral transduction, several restrictions, such as low virus–cell encounters and the necessity for cell division, must be improved. In this study, we focused on the possibility of accelerating cell division and the ensuing increment of viral transduction on flexible substrata. Perfluorocarbon FC‐40 was harnessed to form a liquid–liquid interface with culture medium. Enhanced green fluorescence protein (EGFP) was employed as the marker gene to quickly illustrate the percentage of viral infection. The results indicate that the gene transfer efficiency to 293 cells cultured on protein‐precoated liquid–liquid interfaces was higher than in cells cultured on rigid polystyrene surfaces. This increased transduction rate on the liquid–liquid interface is consistent with the acceleration of division of 293 cells on a flexible interface, which exhibited less adhesiveness. The effect of cell–cell contact inhibition on the rate of gene transduction is also addressed in this study. © 2001 John Wiley & Sons, Inc. Biotechnol Bioeng 72: 331–338, 2001

show abstract

Genetic engineering of stent grafts with a highly efficient pseudotyped retroviral vector

Abstract: VSVG-MuLV significantly increased the gene transfer efficiency in vascular SMCs and ECs and in organ-cultured HSVs. The cells were retained and proliferated on stent grafts for the short term in the pig.

Cited by 24 publications

References 30 publications

High efficiency in vitro gene transfer into vascular tissues using a pseudotyped retroviral vector without pseudotransduction

High efficiency in vitro gene transfer into vascular tissues using a pseudotyped retroviral vector without pseudotransduction

Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease

Enhanced retroviral transduction of 293 cells cultured on liquid-liquid interfaces

Contact Info

Product

Resources

About